A multilaboratory study was performed to establish broth microdilution MIC quality control (QC) guidelines for 10 investigational drugs which previously demonstrated significant activity against Haemophilus influenzae. MIC QC ranges for H. influenzae ATCC 49247 with Haemophilus test medium were determined by using multiple contemporary lots of Haemophilus test medium and the National Committee for Clinical Laboratory Standards' recommended numbers of replicate tests. On the basis of these results, QC ranges (generally modal MIC + one log2 dilution) are proposed for cefdinir, cefepime, cefetamet, cefpirome, ceftibuten, fleroxacin, temafloxacin, clarithromycin, RP59500, and trospectomycin. The proposed QC guidelines for clarithromycin and temafloxacin were recently accepted by the National Committee for Clinical Laboratory Standards.
The susceptibility testing of Haemophilus species strains has been standardized by the National Committee for Clinical Laboratory Standards (NCCLS) by utilizing a modified Mueller-Hinton medium known as Haemophilus test medium (HTM) (3, 11, 12, 14) . The quality of the medium has been questioned (12) , and potential lot-to-lot variations could contribute to interpretive errors or growth failures. Performance criteria for numerous antimicrobial agents that if followed should minimize the routine use of suboptimal HTM lots (12) were reported by Doern et al. (3) . To expand the number of therapeutic agents that can be tested against Haemophilus spp. isolates, we report MIC quality control (QC) guidelines for 10 drugs having significant activity (1, 2, (4) (5) (6) (7) (8) (9) (10) 16) .
Laboratory standard powders were obtained from their U.S. manufacturers, which included Bristol Myers Squibb (Wallingford, Conn.), Hoffmann-LaRoche (Nutley, N.J.), Abbott Laboratories (North Chicago, Ill.), The Upjohn Co. The QC study designs conformed to the NCCLS M23-T guideline (13) . Briefly, the six participant laboratories each received a unique lot of HTM broth in microdilution trays to be replicate tested with the QC strain Haemophilus influenzae ATCC 49247. Each site also processed the organism in a lot of trays common to all laboratories. The total numbers of MIC tests contributed from each laboratory were 20 from the unique lot and 5 tests from the common lot.
Mueller-Hinton broth lots (six total) used to prepare HTM were produced by respective companies as follows: Difco Laboratories (Detroit, Mich.), lots 784256 (common lot) and 766208; Becton Dickinson Microbiology Systems (Cockeysville, Md.), lots 1586X and DlDTOU; Oxoid USA, Inc. 4 ,ug/ml), a practice used previously for amoxicillin-clavulanic acid, cefixime, ceftazidime, ceftizoxime, ciprofloxacin, imipenem, tetracycline, and trimethoprim-sulfamethoxazole (14). Cefetamet MICs produced a clear modal value (1 ,u.g/ml). However, three MICs (2.5%) for the unique lots and one MIC (3.3%) for the common lots were outside the proposed threedilution range. This was an acceptable variance in QC limits. Overall, there was negligible lot-to-lot variation of the MICs obtained with the control strain and the 10 drugs tested. The distributions of MICs determined for common lot and the unique lots were nearly identical ( Table 1) .
The vast majority of the proposed MIC QC guidelines encompass 100% of the results obtained in this study. The QC ranges for the clarithromycin and temafloxacin MICs have been accepted by the NCCLS (15 0.5 to 4 p.g/ml (100%); cefepime, 0.5 to 2 ,ug/ml (100%); cefetamet, 0.5 to 2 ,ug/ml (97.3%); cefpirome, 0.25 to 1 ,ug/ml (100%); ceftibuten, 0.25 to 1 p.g/ml (100%); fleroxacin, 0.03 to 0.12 ,ug/ml (100%); temafloxacin, 0.008 to 0.03 ,ug/ml (100%); clarithromycin, 4 to 16 ,ug/ml (100%); RP59500, 4 to 16 pg/ml (100%); trospectomycin, 0.5 to 2 p.g/ml (100%). The 10 new and investigational compounds evaluated in this study have all been shown to have significant activity against H. influenzae (1, 2, 4-10, 16 ). The MIC QC data summarized should expand the number of drugs which can be reliably tested in HTM broth against Haemophilus spp. during phase III clinical trials and after approval by the Food and Drug Administration.
